Genmab (GMAB) Stock Analysis & Forecast

Nov 13 close

$51.37−0.37 (−0.7%)

Gekko Brief

AI summaryNov 13 close

Genmab's week centers on petosemtamab, which combined with Merck's Keytruda cut death risk by 50% in first-line head and neck cancer patients in the Phase 3 LiGeR-HN1 trial, meeting both overall survival and objective response rate endpoints. Shares also rose 4% after partner Johnson & Johnson secured FDA approval for Rybrevant Fasbro in head and neck cancer, on which Genmab is set to receive royalties of 8% to 10% on net sales. Several directors and CEO Jan van de Winkel disclosed share sales during the period, alongside a capital increase tied to employee warrant exercises.

GMAB closed at $51.37, down 0.7%, with the stock trading well above both its 50-day average of $41.15 and 200-day average of $31.54, reflecting a sustained uptrend; the 1-month return stands at 35.8% and the 1-year return at 68.6%. The GekkoIndex reads 53.4, placing the stock in the Neutral zone. Price sits 9.5% above Gekko Fair Value of $46.91.

The next earnings date is 16 February 2027, 94 days out, beyond a typical 20-trading-day hold. Over the last 30 days, one unusual options signal was recorded, with call premium of $4.3 million against no put premium. Consensus among 9 analysts stands at 8 buy and 1 hold ratings, with a consensus target of $65.11. Seasonality over the next 20 trading days has averaged -2.2% across 5 years, rising in 2 of them.

Written by AI from the Nov 13, 2026 close and checked automatically against the figures on this page.

Genmab price vs fair value

$51.37$47.13Nov ’25May ’26Nov ’26
Close $51.37200-day averageGekko Fair Value $47.13

Genmab quick facts

Market cap
$31.67B
P/E ratio
44.2
Forward P/E
23
EPS, TTM
$1.17
Revenue, TTM
$4.30B
Profit margin
17%
Dividend yield
—
Beta
0.52
Volume
3.73M avg 6.51M
1-year return
+68.6%
Typical daily move
±6.1%
Typical 20-day move
±6.9%
50-day average
$41.15
200-day average
$31.54
Next earnings
Feb 16
Shares outstanding
616.6M
52-week range
$23.62$59.97

Genmab swing-trade checklist

Genmab scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $51.37 is above the 50-day ($41.15) and 200-day ($31.54) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.4, Neutral

    Reading 53.4 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    9.0% above

    Price is 9% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 93 days

    Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −1.4% on average

    From this point in the calendar, the next 20 trading days averaged −1.4% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Genmab stock chart and price history

Genmab closed at $51.37 on Nov 13, 2026, +68.6% over the past year, inside a 52-week range of $23.62 to $59.97.

Close50-day average200-day averageVolume
Genmab share price, past year, with 50-day and 200-day moving averages and volume$30$40DecJan 2026FebMarAprMayJunJulAugSepOctNov51.37

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+35.8%
3 months
+56.4%
6 months
+93.6%
1 year
+68.6%
The full GMAB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GMAB in Gekko

Follow Genmab through every session

Put GMAB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track GMAB in GekkoFree for 7 days. No credit card required.

About Genmab

Genmab works in biopharmaceuticals, focusing on discovering and developing antibody-based treatments, mainly for cancer along with a handful of other serious conditions. It is known for its marketed antibody therapies, including a treatment for multiple myeloma and related blood cancers, one for thyroid eye disease, one used in chronic lymphocytic leukemia and multiple sclerosis, another for certain gastric, esophageal and lung cancers, and one aimed at cervical and ovarian cancers and other solid tumors.

Beyond its approved products, Genmab runs a wide pipeline of experimental antibodies at various clinical stages, targeting solid tumors and blood cancers, alongside roughly twenty early pre-clinical programs. Much of this work is carried out through partnerships rather than alone, with agreements covering commercialization and co-development, mRNA-based antibody research, and other joint development deals with several pharmaceutical and biotech partners.

Genmab was established in 1999 and is headquartered in Copenhagen, Denmark. Its shares trade under the ticker GMAB.

Sector
Health technology
Website
genmab.com

Genmab GekkoIndex: the smart money zone

Genmab’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.4, in the Neutral zone, up 6.6 points over five sessions.

010053.4Neutral

Up 6.6 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying47−0.6%0.0%+1.0%−2.5%
Accumulation218+0.5%+1.0%+1.9%+3.5%
Neutral (current zone)344+0.7%+1.4%+1.5%+2.5%
Distribution43+2.4%+1.8%+6.7%+23.1%
Selling3Too few readings yet

Average GMAB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the GMAB price, zone by zone.Track GMAB in Gekko

Is Genmab stock overvalued? Gekko Fair Value

Genmab trades 9.0% above Gekko Fair Value of $47.13, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Genmab shares are worth, recalculated every trading day.

$47.13

Gekko Fair Value, Nov 14, 2026

9.0% Overvalued

At the end of Aug 2026 the price was 7.0% below the estimate.

Gekko Fair ValueShare price, month end
$47$51Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open GMAB in Gekko

Genmab insider and Congress trading

No open-market insider purchases were filed for Genmab, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for GMAB in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every GMAB insider filing, plotted on the chart in Gekko.Open GMAB in Gekko

Congress trades last 90 days

No trades in GMAB were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for GMAB, plotted on the chart in Gekko.Open GMAB in Gekko

Buybacks

Genmab has been buying back its own shares.

Bought back, quarter ended Mar 31, 2026
$96.36M
As a share of market cap
0.30%
Trailing four quarters
$526.7M

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bearish flow on Oct 29, $4.29M in unusual premium.

Hedge funds and billionaires quarter ended Mar 31

0of the funds Gekko tracks hold GMAB.

0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Genmab earnings: next date and track record

Genmab reports on Feb 16, 2027 (93 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±4.6%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

+10.7%Feb ’25−6.0%May ’25−0.4%Aug ’25−1.8%Nov ’25−2.9%Feb ’26−5.2%May ’26+6.8%Aug ’26−2.7%Nov ’26

Last earnings call, Nov 5, 2026 AI summary

What they said
Genmab reported 22% total revenue growth for the first nine months of 2026, with adjusted operating profit up 9%. Three Phase III trials produced positive readouts in October: EPKINLY met PFS endpoint (HR 0.49) in frontline DLBCL, Rina-S met both PFS (HR 0.29) and OS endpoints in platinum-resistant ovarian cancer, and petosemtamab met dual OS (HR 0.5) and ORR endpoints in first-line head and neck cancer. Commercial products EPKINLY and TIVDAK continue strong market performance.
Guidance
LiGeR-HN2 trial readout for petosemtamab in second/third-line head and neck cancer expected Q1 2027. Rina-S expansion targets ovarian and endometrial cancers beyond initial launch indication. Management expressed confidence in commercialization capabilities across all three programs pending regulatory approval.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 5, 2026$0.56
est $0.36
+55.6%$1.19B
est $1.20B
−0.9%−2.7%
Aug 6, 2026$0.54
est $0.37
+45.9%$1.16B
est $1.12B
+3.5%+6.8%
May 7, 2026$0.13
est $0.19
−31.6%$896.0M
est $905.8M
−1.1%−5.2%
Feb 17, 2026$0.21
est $0.37
−43.2%$1.06B
est $1.07B
−0.8%−2.9%
Nov 6, 2025$0.65
est $0.45
+44.4%$1.02B
est $1.01B
+1.1%−1.8%
Aug 7, 2025$0.54
est $0.34
+58.8%$924.8M
est $952.6M
−2.9%−0.4%
May 8, 2025$0.31
est $0.23
+34.8%$726.0M
est $755.5M
−3.9%−6.0%
Feb 12, 2025$0.84
est $0.28
+200.0%$891.4M
est $791.9M
+12.6%+10.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Genmab stock forecast and analyst price targets

Analysts’ average 12-month price target for Genmab is $65.10, +26.7% from the last close, from 9 firms rating the stock in the last 90 days.

$65.10consensus 12-month target, +26.7% from the last close
Low $52High $70
Buy8
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyHold, maintained$56+9.0%
Nov 6Truist FinancialBuy, maintained$67+30.4%
Nov 6Morgan StanleyHold, maintained$57+11.0%
Nov 6H.C. WainwrightBuy, reiterated$70+36.3%
Nov 6Bank of America SecuritiesBuy, maintained——
+1.5%average 20-day move after past Neutral readings
−1.4%average move over the next 20 trading days in the last 5 years
±6.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Genmab seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Genmab averaged −1.4% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−12.9%2021+8.0%2022−1.7%2023−4.8%2024+4.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.6%2 of 5
Next 10 trading days−0.9%2 of 5
Next 15 trading days+1.3%3 of 5
Next 20 trading days−1.4%2 of 5
Next 30 trading days−1.0%1 of 5

For scale, GMAB’s typical 20-trading-day move in either direction is about 6.9%.

Genmab market cap and key statistics

Genmab’s market cap is $31.67B, with a P/E ratio of 44.2 and revenue of $4.30B over the last twelve months.

Valuation

Market cap
$31.67B
P/E ratio
44.2
Forward P/E
23
EPS, TTM
$1.17
Gekko Fair Value
$47.13

Trading

Volume
3.73M
Avg volume, 20 days
6.51M
52-week high
$59.97
52-week low
$23.62
Shares outstanding
616.6M

Financials

Revenue, TTM
$4.30B
Profit margin
17%
Return on equity
12.1%
Quarterly earnings growth, YoY
−14.7%

Risk and income

Beta
0.52
Typical daily move
±6.1%
Typical 20-day move
±6.9%

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

Genmab stock FAQ

What is Genmab’s market cap?

Genmab’s market cap is $31.67B at the Nov 13, 2026 close of $51.37, with 616.6M shares outstanding. The shares trade on a P/E ratio of 44.2.

What is the Genmab stock forecast?

The consensus analyst 12-month price target for Genmab is $65.10, +26.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Genmab stock overvalued or undervalued?

On Gekko’s estimate Genmab is overvalued: the Nov 13, 2026 close of $51.37 is 9.0% above Gekko Fair Value of $47.13. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Genmab report earnings next?

Genmab is expected to report on Feb 16, 2027 (93 days away). Analysts expect earnings of $0.23 per share on revenue of $1.25B. Genmab beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.

What is Genmab’s 52-week high and low?

Genmab’s 52-week high is $59.97 and its 52-week low is $23.62; it closed at $51.37 on Nov 13, 2026, +68.6% over the past year.

Is Genmab stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Genmab?

Gekko flagged 1 unusual options signal in Genmab over the last 30 days, with $4.29M of flagged premium in calls and $0 in puts. The latest, bearish flow, was on Oct 29, 2026 with $4.29M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Genmab the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.